undefined undefined undefined

Secondary prevention of cardiovascular disease

Event: ESC Congress 2025

Topic: Secondary Prevention

Session type: ePoster Rounds

Access

Like

Beyond antithrombotic therapies in PCI: role of lipids, inflammation, and therapies on the horizon

Event: ESC Congress 2023

Topic: Percutaneous Coronary Intervention (PCI)

Session type: Advances in Science

Access

Like

The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management

Event: ESC Congress 2023

Topic: Lipid-Lowering Agents

Session type: Satellite Symposium

Access

Like

Lipids 3

Event: ESC Congress 2022

Topic: Lipids

Session type: Moderated ePosters

Access

Like

A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session type: Satellite Symposium

Access

Like

Cardiovascular risk assessment - Biomarkers 1

Event: ESC Congress 2022

Topic: Biomarkers

Session type: Moderated ePosters

Access

Like

LDL lowering – dealing with difficult situations

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacology and Pharmacotherapy

Session type: Cardiology Toolbox

Access

Like

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Access

Like

Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease

Event: ESC Congress 2020

Topic: Treatment

Session type: Industry Live

Access

Like

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

Event: ESC Congress 2020

Topic: Treatment

Session type: Industry Q&A session

Access

Like

undefined undefined undefined

Contributor content

Secondary prevention of cardiovascular disease

Beyond antithrombotic therapies in PCI: role of lipids, inflammation, and therapies on the horizon

The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management

Lipids 3

A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)

Cardiovascular risk assessment - Biomarkers 1

LDL lowering – dealing with difficult situations

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

ESC 365 is supported by